Last reviewed · How we verify
NCT07145502
Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory Syndromes
trial testing Allogeneic MSC infusions (IV) in Autoimmune Encephalitis in 76 participants. Participants enrolled and being followed up; not accepting new ones.
15 July 2024
Quick facts
| Lead sponsor | Biocells Medical |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 76 |
| Start date | 19 September 2022 |
| Primary completion | 15 July 2024 |
| Estimated completion | 19 September 2027 |
| Sites | 1 location across Poland |
Drugs / interventions tested
- Allogeneic MSC infusions (IV) — full drug profile →
Conditions studied
- Autoimmune Encephalitis — all drugs for Autoimmune Encephalitis →
- Early-stage Panencephalitis — all drugs for Early-stage Panencephalitis →
- Neuroinflammatory Demyelination — all drugs for Neuroinflammatory Demyelination →
Sponsor
Biocells Medical — full company profile →
Who can join
Adults 6 to 70, any sex, with Autoimmune Encephalitis or Early-stage Panencephalitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, non-randomized, observational registry study evaluating the clinical outcomes of patients with autoimmune or post-infectious neuroinflammatory syndromes receiving stem cell-derived biologics (including mesenchymal stem cells and exosomes) at Biocells Medical clinics. The study aims to track improvements in neurological function, inflammatory biomarkers, and patient-reported quality of life following individualized regenerative interventions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic challenges in central nervous system viral infections: advancing mesenchymal stem cell-based strategies for treating neuroinflammation and promoting tissue repair.
Carbone-Schellman J, Fontecilla-Escobar J, Sales-Salinas N, Chaparro-Pico WF, et al · · 2025 · cited 1× · PMID 41235241 · DOI 10.3389/fimmu.2025.1677433 -
Extracellular Vesicles in Autoimmune Diseases: From Diagnostic Biomarkers to Engineered Therapeutics.
Wu Y, Ma H, Zhu T, Huang S, et al · · 2026 · PMID 41677384 · DOI 10.1002/advs.202521802
Verify or expand the search:
- PubMed search for NCT07145502
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Autoimmune Encephalitis
Currently open trials in the same condition.
- NCT07477015 — Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune Encephalitis · recruiting
- NCT06753955 — Phase 1 Study of ART5803 Safety and PK After IVIG in Healthy Participants · Phase 1 · active not recruiting
- NCT06575153 — Phase 1 Study of ART5803 in Healthy Participants · Phase 1 · active not recruiting
- NCT06079294 — Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism · NA · recruiting
- NCT06432803 — Metabolic Imaging for Diagnosis and Prognostication of Autoimmune encephalitiS · active not recruiting
Other Biocells Medical trials
Trials by the same sponsor.
- NCT07471230 — Evaluation of Neuroinduced Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Exosomes in Patients With Parkinsoni · Phase 2 · not yet recruiting
- NCT07465198 — Autologous Stem Cell Therapy in Patients With Multiple System Atrophy · Phase 2 · not yet recruiting
- NCT07467733 — Evaluation of the Safety and Preliminary Efficacy of Neuroinduced Mesenchymal Stem Cells and Exosome Therapy in Patients · Phase 1, PHASE2 · not yet recruiting
- NCT07143656 — Amyotrophic Lateral Sclerosis: A Multicenter Retrospective Observational Registry · active not recruiting
- NCT07146087 — Allogeneic Mesenchymal Stem Cell-Derived Exosome Therapy for Progressive Multiple Sclerosis · EARLY_PHASE1 · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07145502 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Biocells Medical
- Last refreshed: 5 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07145502.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing